Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion

Shahid Beheshti University of Medical Sciences90 enrolled

Overview

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Branch Retinal Vein Occlusion

Interventions

BevacizumabDRUG

Intravitreal, 1.25 mg, 3 times, one month apart.

Triamcinolone AcetonideDRUG

Intravitreal, 2 mg, 2 times, two months apart.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Recent onset (less than 3 months) BRVO Exclusion Criteria: * Any previous intervention

Locations (1)

Imam Hossein medical center

Tehran, Iran

RECRUITING

Outcomes

Primary Outcomes

Visual acuity

Time frame: 6 months

Secondary Outcomes

central macular thickness

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.